Drug Profile

LIB 01

Alternative Names: DIC-2024; LIB-01; Libiguin®; Libiguin® DIC2024

Latest Information Update: 26 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Uppsala University
Developer Dicot
Class Erectile dysfunction therapies; Small molecules
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Erectile dysfunction
Preclinical Premature ejaculation

Most Recent Events

19 Dec 2024 Dicot has patent family granted for LIB 01 in USA
11 Nov 2024 Dicot Pharma receives a Notice of Allowance from the USPTO for "New Compounds and Methods of Their Manufacturing" of LIB 01 in the US
08 Nov 2024 Phase-II clinical trials in Erectile dysfunction (In adults) in Denmark (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com